Prot #DV3-MEL-01: A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Project: Research project

Project Details

StatusFinished
Effective start/end date10/3/17 → 10/3/20

Funding

  • PRA Health Sciences (Prot #DV3-MEL-01 // Prot #DV3-MEL-01)
  • Dynavax Technologies Corporation (Prot #DV3-MEL-01 // Prot #DV3-MEL-01)